Stalicla
Stalicla was founded in 2017, is headquartered in Genève, Switzerland, and has $17.4M in recorded funding across 2 rounds.
- Headquarters
- Genève
- Founded
- 2017
- Website
- stalicla.com
- Total Funding
- $17.4M
- Last Round
- Series CJun 2025
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.
About
STALICLA, which was founded in May 2017 by CEO Lynn Durham, is attempting to identify subgroups of patients with idiopathic ASD by utilizing a big data approach, and then planning to treat them using combinations of repurposed drugs. Its Drug Development Unit combines expertise in operations, medicine, and clinical development to bring STALICLA's clinical-stage treatment options closer to patients.
Summary
Stalicla is a Biotech company based in Genève, Switzerland, founded in 2017. It has raised $17.4M in total across 2 rounds, most recently a Series C round in Jun 2025. Investors include SPRIM Global Investments.
Funding History
Jun 2025
Sign up to see all 2 events
Funding: Series B through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
Altos Labs combines academic science and industry development to create medicines that restore ce...
BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Calico researches human aging using advanced technologies and model systems, applying that knowle...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/stalicla"><img src="https://indexed.vc/api/badge/company/stalicla" alt="Stalicla on Indexed.vc" width="260" height="76" /></a>